BioPharma Dive January 6, 2025
Every presidential election brings change to the Food and Drug Administration. This time around, the upheaval could be particularly jarring.
The nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services, which oversees the FDA and other health agencies, brings new uncertainty to the regulator’s future. Even with Marty Makary — viewed as a more traditional pick for FDA Commissioner — possibly leading the regulator, Kennedy’s presence would have broad implications for the agency and its workforce. Three high-ranking officials have already...
Today's Sponsors
Today's Sponsor